4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
4DMedical Limited - Special Call Company Participants Andreas Fouras - Founder, MD, CEO & Director Conference Call Participants Thomas Godfrey - Ord Minnett Limited, Research Division Kyle Hogarth Presentation Thomas Godfrey Ord Minnett Limited, Research Division Fantastic. I think we're live.
| - Industry | - Sector | Dr. Andreas Fouras M.A.I.C.D., Ph.D. CEO | OTC PINK Exchange | AU0000095416 ISIN |
| AU Country | 145 Employees | - Last Dividend | - Last Split | - IPO Date |
4DMedical Limited is a forefront medical technology company with operational bases in Australia and the United States. Established in 2012 and headquartered in Carlton, Australia, the company specializes in the commercialization of its proprietary four-dimensional lung imaging technology, known as XV Technology. This innovative approach aims to revolutionize the diagnosis and management of pulmonary conditions by providing detailed and dynamic images of lung function. Additionally, 4DMedical offers its products and services through a software as a service (SaaS) delivery model, striving to enhance accessibility and efficiency for healthcare professionals and researchers worldwide.
This is 4DMedical's flagship four-dimensional lung imaging technology, designed to offer unprecedented insights into lung function and ventilation dynamics. By capturing detailed, time-sequenced images of the lungs as they fill and empty of air, this advanced imaging solution provides clinicians with a deeper understanding of pulmonary conditions, facilitating more accurate diagnoses and personalized treatment plans.
4DMedical capitalizes on cloud computing to offer its XV lungs ventilation analysis software and other applications as a service over the internet. This model eliminates the need for extensive hardware by clients, reduces upfront costs, and provides flexibility and scalability to accommodate varying organizational requirements.
A cornerstone of 4DMedical’s offering, this software enables the detailed analysis of lung function utilizing the data generated by XV Technology. It provides healthcare professionals with a comprehensive suite of tools for assessing ventilation heterogeneity and other functional parameters critical for diagnosing and managing pulmonary diseases.
This preclinical imaging system is specifically designed to quantify regional changes in pulmonary function. Permetium is aimed at researchers working on respiratory conditions, providing detailed images and functional insights that can dramatically enhance the understanding of disease mechanisms and the effects of therapeutic interventions.
A sophisticated small animal ventilator, AccuVent 200 complements 4DMedical's suite of pulmonary analysis tools by facilitating precise ventilation control during imaging procedures. This equipment is crucial for preclinical studies that require detailed and consistent respiratory management to ensure the accuracy of pulmonary function assessments.